Although serum potassium monitoring is recommended to reduce the risk of hyperkalemia, only a small percentage of patients taking RAAS inhibitors are monitored. Hyperkalemia diagnosis is often missed ...

Over the weekend AliveCor announced that its technology was validated in two studies. The first found that its KardiaBand, which works as a personal electrocardiogram device, can accurately detect ...

Please provide your email address to receive an email when new articles are posted on . Hyperkalemia is a relatively common transient acute electrolyte abnormality. Due to its propensity to cause ...

Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin–angiotensin–aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a ...

AliveCor’s KardiaBand is the first Apple Watch accessory to gain FDA approval, allowing users to get an electrocardiogram (EKG) reading right from their smart band. Naturally, you can use that to take ...

A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications ...

Hyperkalemia is a potentially serious condition that can result in life-threatening cardiac arrhythmias and is associated with an increased mortality risk. Patients older than 65 years who have an ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

Hyperkalemia is associated with increased mortality risk. A recent study examined whether rapid correction of elevated serum potassium level (K+) was associated with reduced mortality in patients ...

Hyperkalemia is a condition where potassium levels in the blood are abnormally high. Anyone can develop it, but certain people, such as those with kidney dysfunction, have an increased risk. Having ...